Therefore, this systematic review and meta-analysis aimed to determine the pooled standardized mean differences (SMD) of GFAP and NfL between COVID-19 patients and healthy controls, generating evidence for the association between neurological injury-related biomarkers and COVID-19 prognosis. This evidence concerns the gene NEFL and COVID-19.